Akebia Therapeutics AKBA 深 滬
等待開盤 10-29 09:30:00 美东时间
3.105
-0.065
-2.05%
華盛通- 最 高3.168
- 今 開3.16
- 成交量 164.15万股
- 最 低 3.07
- 昨 收 3.17
- 總市值 8.23亿
- 52周最高 4.0787
- 市盈率 靜 --
- 換手率 0.62%
- 52周最低 1.52
- 委 比 -54.20%
- 總股本 2.65亿
- 歷史最高 31.00
- 量 比 0.81
- 振 幅 3.09%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Akebia Therapeutics will present data on Vafseo® (vadadustat) at ASN Kidney Week 2025, sharing insights on its clinical benefits, dosing, and real-world studies. The research includes a win odds analysis comparing vadadustat with darbepoetin alfa for CKD-related anemia, as well as posters on dosing recommendations and ongoing trials like VOICE and VOCAL. The company emphasizes its commitment to advancing understanding of Vafseo and providing evid...
10-20 12:08
Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics executives will participate in two investor conferences in September: the Wells Fargo Healthcare Conference on September 4, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. A webcast of each presentation will be available on Akebia’s website post-conference.
08-28 12:00
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Akebia Therapeutics and Innovative Renal Care (IRC) announce the broad availability of Vafseo (vadadustat) for treating anemia in chronic kidney disease (CKD) patients on dialysis across IRC's over 230 US clinics. Approved by the FDA in March 2024, Vafseo is now accessible to thousands of IRC patients, supported by standardized treatment protocols. IRC's Chief Medical Officer, Dr. Geoffrey Walker, emphasizes their patient-centered approach throug...
08-21 12:00
Akebia Therapeutics shares are trading lower following the release of its Q2 financial results.
Akebia Therapeutics shares are trading lower following the release of its Q2 fi...
08-07 21:01
Akebia Therapeutics Q2 Sales $62.472M Beat $47.637M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47.637 million by 31.14 percent. This is a 43.13 percent increase over sales of $43.648 million
08-07 19:03
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Earnings Preview For Akebia Therapeutics
Akebia Therapeutics (NASDAQ:AKBA) is preparing to release its quarterly earning...
08-07 03:03
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Akebia Therapeutics, a biopharmaceutical company focused on improving lives affected by kidney disease, announced that CEO John P. Butler will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 13, 2025, at 1:30 PM EDT in Boston. A webcast of the presentation will be available on Akebia’s investor website following the conference.
08-06 12:00
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Akebia Therapeutics has initiated the VOCAL trial, a post-marketing study, to evaluate the benefits of treating patients with Vafseo three times a week. The trial, conducted at DaVita dialysis clinics, aims to assess the efficacy and safety of vadadustat compared to standard ESAs in patients with anemia due to CKD under in-center hemodialysis. Approximately 350 patients will be enrolled, with sub-studies focusing on RBC quality. The study expects...
08-04 12:00
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics will release its Q2 2025 financial results on August 7, 2025, and host a conference call at 8:00 a.m. EDT. Registration is required via the link provided, and participants should dial in 15 minutes early. A live webcast and archived version will be available on Akebia’s Investors website.
07-31 12:00
